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It is clearly accepted that all vaccines are adjuvanted (endogenously: part of the pathogen or exogenously: 
added to the antigen formulation) except for a few vaccines such as liquid Hib or non aluminic Meningitis 
vaccines .It is also recognized that the vast majority of recombinant vaccines if not all, will require an adjuvant to 
induce an immune response which will be adequate in quality and quantity. Over the past 3 decades, adjuvants 
have become increasingly important and central to the development of new and improved vaccines. Although 
the introduction of exogenously adjuvanted vaccine has been slow and steady, 7 licensed vaccines based in the 
adjuvanted approach are now licensed, and the number eaching late development phase continue to increase.  
 
Their introduction into vaccines has added complexity to the development of vaccines in terms of formulation, 
preclinical and safety evaluation both preclinically and clinically.  
 
Challenges however remain and should be understood and overcome when embarking in the development of a 
new adjuvant antigen combination. It is only the combination of the right antigen and the right adjuvant that will 
lead to an efficacious vaccine, in that sense, one cannot be assessed without the other, in particular in the 
context of the formulation. Special consideration need to be taken when defining and evaluating the formulation 
aspect of the vaccine.The preclinical evaluation needs to take into account the nature of the adjuvant used and 
its potential differences between species. Understanding adjuvant mode of action has therefore become crucial, 
with the realization that differences existed between animals and humans making extrapolation between 
preclinical and clinical not always possible. The use of adjuvants in new vaccines has highlighted the need to 
define preclinical and clinical safety evaluation methods as compared to therapeutic small molecules 
 
This presentation will review the challenges faced with the development of adjuvanted vaccines, from their 
inception to current days, and path that could be followed. 
 
 
